{"id":4789,"date":"2019-04-18T12:21:22","date_gmt":"2019-04-18T06:51:22","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4789"},"modified":"2021-07-24T12:57:17","modified_gmt":"2021-07-24T07:27:17","slug":"the-business-cocktail-evenity","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-evenity","title":{"rendered":"Amgen reveals price; Bardy raises $35.5M; Kiadis to Acquire CytoSen; Insitro lands a deal"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a12ee631c664\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a12ee631c664\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-evenity\/#Amgen_reveals_the_price_of_EVENITY\" >Amgen reveals the\nprice of EVENITY<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-evenity\/#Bardy_Diagnostics_raises_USD_355_Million\" >Bardy Diagnostics raises USD 35.5 Million<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-evenity\/#Kiadis_to_Acquire_CytoSen_Therapeutics_for_194_million_shares\" >Kiadis to Acquire\nCytoSen Therapeutics for 1.94\nmillion shares<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-evenity\/#Insitro_lands_a_deal_with_Gilead_worth_USD_15_million\" >Insitro lands a deal\nwith Gilead worth USD 15 million<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Amgen_reveals_the_price_of_EVENITY\"><\/span><strong>Amgen reveals the\nprice of EVENITY <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Amgen<\/strong> has set the price of its newly launched Osteoporosis drug <strong>Romosozumab<\/strong> (Evenity). Worth <strong>USD<\/strong> <strong>21,900 per annum<\/strong> or USD 1,825 a month,<strong> the bone-building drug<\/strong> was approved by the FDA recently for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/post-menopausal-osteoporosis-market\">Osteoporosis in postmenopausal <\/a>women and now will be available in the U.S. The price of <strong>Evenity <\/strong>is 34-74% lower than the cost of other available drugs like Tymlos of Radius Health and Forteo of Eli Lilly. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bardy_Diagnostics_raises_USD_355_Million\"><\/span><strong>Bardy Diagnostics raises USD 35.5 Million<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Bardy Diagnostics, <\/strong>an American based leading provider of ambulatory cardiac monitoring technologies has raised <strong>USD 35.5 million<\/strong>. The Series B funding was led by River Cities Capital Funds. The funds will help Bardy to boost the growth of its innovative <strong>cardiac monitoring platform<\/strong>, intelligence and visualization technologies, expansion of its sales and monitoring services. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Kiadis_to_Acquire_CytoSen_Therapeutics_for_194_million_shares\"><\/span><strong>Kiadis to Acquire\nCytoSen Therapeutics<\/strong> <strong>for 1.94\nmillion shares<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Kiadis Pharma NV, <\/strong>a Dutch biotech is all set to buy <strong>CytoSen Therapeutics, <\/strong>which has been working on NK cell platform to enable <strong>NK cell thera<\/strong>py with broad anti-cancer potential. Kiadis is focused on developing <strong>ATIR101 <\/strong>a drug ought to bring positive results in treating Cancer specifically for patients undergoing <strong>haploidentical hematopoietic stem cell transplants (HSCT). <\/strong>The joint deal will provide promising treatment options by combining T-cell therapies with NK cells.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Insitro_lands_a_deal_with_Gilead_worth_USD_15_million\"><\/span><strong>Insitro lands a deal\nwith Gilead worth USD 15 million<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Insitro, <\/strong>a California-based drug discovery startup has inked a three-year pact with the pharma giant <strong>Gilead<\/strong>. The collaboration will require Gilead to fund Insitro to help the latter to find medicines to treat <strong>liver<\/strong> <strong>disease<\/strong>, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/nonalcoholic-steatohepatitis-nash-market\"><strong>NonAlcoholic<\/strong> <strong>Steatohepatitis<\/strong><\/a> (<strong>NASH<\/strong>). Insitro, with all the financial help, will be able to improve drug discovery and regulate the enormous data with the use of its advanced computing tools.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Amgen reveals the price of EVENITY Amgen has set the price of its newly launched Osteoporosis drug Romosozumab (Evenity). Worth USD 21,900 per annum or USD 1,825 a month, the bone-building drug was approved by the FDA recently for the treatment of Osteoporosis in postmenopausal women and now will be available in the U.S. The [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4790,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[3381,3377,3384,3386,3385,1500,3284,3378],"industry":[17225],"therapeutic_areas":[17239,17241,17228,17411],"class_list":["post-4789","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cytosen-therapeutics","tag-evenity","tag-insitro","tag-kiadis-pharma","tag-nk-cell","tag-osteoporosis","tag-post-menopausal-osteoporosis","tag-tymlos","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-musculoskeletal","therapeutic_areas-oncology","therapeutic_areas-womens-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Amgen reveals price; Bardy raises $35.5M; Kiadis to Acquire CytoSen<\/title>\n<meta name=\"description\" content=\"Amgen has set the price of its newly launched Osteoporosis drug Romosozumab (Evenity). Worth USD 21,900 per annum, its price is 34-74% lower than the...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-evenity\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen reveals price; Bardy raises $35.5M; Kiadis to Acquire CytoSen\" \/>\n<meta property=\"og:description\" content=\"Amgen has set the price of its newly launched Osteoporosis drug Romosozumab (Evenity). Worth USD 21,900 per annum, its price is 34-74% lower than the...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-evenity\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-18T06:51:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09024709\/My-Post-4.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Amgen reveals price; Bardy raises $35.5M; Kiadis to Acquire CytoSen","description":"Amgen has set the price of its newly launched Osteoporosis drug Romosozumab (Evenity). Worth USD 21,900 per annum, its price is 34-74% lower than the...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-evenity","og_locale":"en_US","og_type":"article","og_title":"Amgen reveals price; Bardy raises $35.5M; Kiadis to Acquire CytoSen","og_description":"Amgen has set the price of its newly launched Osteoporosis drug Romosozumab (Evenity). Worth USD 21,900 per annum, its price is 34-74% lower than the...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-evenity","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-04-18T06:51:22+00:00","article_modified_time":"2021-07-24T07:27:17+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09024709\/My-Post-4.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-evenity","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-evenity","name":"Amgen reveals price; Bardy raises $35.5M; Kiadis to Acquire CytoSen","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-evenity#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-evenity#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09024709\/My-Post-4.jpg","datePublished":"2019-04-18T06:51:22+00:00","dateModified":"2021-07-24T07:27:17+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Amgen has set the price of its newly launched Osteoporosis drug Romosozumab (Evenity). Worth USD 21,900 per annum, its price is 34-74% lower than the...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-evenity"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-evenity#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09024709\/My-Post-4.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09024709\/My-Post-4.jpg","width":647,"height":345},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09024709\/My-Post-4-300x160.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cytosen Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Evenity<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Insitro<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Kiadis Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NK Cell<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Osteoporosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Post menopausal Osteoporosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tymlos<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cytosen Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Evenity<\/span>","<span class=\"advgb-post-tax-term\">Insitro<\/span>","<span class=\"advgb-post-tax-term\">Kiadis Pharma<\/span>","<span class=\"advgb-post-tax-term\">NK Cell<\/span>","<span class=\"advgb-post-tax-term\">Osteoporosis<\/span>","<span class=\"advgb-post-tax-term\">Post menopausal Osteoporosis<\/span>","<span class=\"advgb-post-tax-term\">Tymlos<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Apr 18, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Apr 18, 2019 12:21 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4789"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4789\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4790"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4789"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4789"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}